These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

850 related items for PubMed ID: 26675344

  • 1. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients.
    Di Domenico F, Pupo G, Giraldo E, Badìa MC, Monllor P, Lloret A, Schininà ME, Giorgi A, Cini C, Tramutola A, Butterfield DA, Viña J, Perluigi M.
    Free Radic Biol Med; 2016 Feb; 91():1-9. PubMed ID: 26675344
    [Abstract] [Full Text] [Related]

  • 2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [Abstract] [Full Text] [Related]

  • 3. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.
    Vos SJ, van Rossum IA, Verhey F, Knol DL, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Frisoni GB, Froelich L, Nobili F, van der Flier W, Blennow K, Wolz R, Scheltens P, Visser PJ.
    Neurology; 2013 Mar 19; 80(12):1124-32. PubMed ID: 23446677
    [Abstract] [Full Text] [Related]

  • 4. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV, Aprahamian I, Radanovic M, Talib LL, Camargo MZ, Stella F, Machado-Vieira R, Gattaz WF.
    Bipolar Disord; 2016 Feb 19; 18(1):63-70. PubMed ID: 26876913
    [Abstract] [Full Text] [Related]

  • 5. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.
    Arch Gen Psychiatry; 2012 Jan 19; 69(1):98-106. PubMed ID: 22213792
    [Abstract] [Full Text] [Related]

  • 6. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.
    J Alzheimers Dis; 2015 Jan 19; 44(2):525-39. PubMed ID: 25391385
    [Abstract] [Full Text] [Related]

  • 7. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
    Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Handels R, L'Italien G, van der Flier W, Aalten P, Teunissen C, Barkhof F, Blennow K, Wolz R, Rueckert D, Verhey F, Visser PJ.
    Neurobiol Aging; 2012 Oct 19; 33(10):2272-81. PubMed ID: 22264648
    [Abstract] [Full Text] [Related]

  • 8. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J, Gholamrezaee M, Henry H, von Gunten A, Popp J.
    Exp Gerontol; 2017 Dec 15; 100():45-53. PubMed ID: 29054536
    [Abstract] [Full Text] [Related]

  • 9. Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers.
    Khoonsari PE, Shevchenko G, Herman S, Remnestål J, Giedraitis V, Brundin R, Degerman Gunnarsson M, Kilander L, Zetterberg H, Nilsson P, Lannfelt L, Ingelsson M, Kultima K.
    J Alzheimers Dis; 2019 Dec 15; 67(2):639-651. PubMed ID: 30614806
    [Abstract] [Full Text] [Related]

  • 10. Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline.
    Eliassen CF, Reinvang I, Selnes P, Grambaite R, Fladby T, Hessen E.
    Brain Behav; 2017 Sep 15; 7(9):e00776. PubMed ID: 28948074
    [Abstract] [Full Text] [Related]

  • 11. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
    Alcolea D, Carmona-Iragui M, Suárez-Calvet M, Sánchez-Saudinós MB, Sala I, Antón-Aguirre S, Blesa R, Clarimón J, Fortea J, Lleó A.
    J Alzheimers Dis; 2014 Sep 15; 42(1):157-67. PubMed ID: 24820015
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
    Mroczko B, Groblewska M, Zboch M, Muszyński P, Zajkowska A, Borawska R, Szmitkowski M, Kornhuber J, Lewczuk P.
    J Alzheimers Dis; 2015 Sep 15; 43(3):1031-7. PubMed ID: 25159667
    [Abstract] [Full Text] [Related]

  • 13. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S, Santangelo R, Bernasconi MP, Cecchetti G, Fiorino A, Pinto P, Passerini G, Falautano M, Comi G, Magnani G.
    J Alzheimers Dis; 2016 Oct 18; 54(4):1495-1508. PubMed ID: 27589522
    [Abstract] [Full Text] [Related]

  • 14. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M, DidierLaurent G, Latarche C, Escanyé MC, Olivier JL, Malaplate-Armand C.
    J Alzheimers Dis; 2014 Oct 18; 41(2):377-86. PubMed ID: 24614902
    [Abstract] [Full Text] [Related]

  • 15. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M, Budziszewska M, Barczak A, Pepłońska B, Chodakowska-Żebrowska M, Filipek-Gliszczyńska A, Nesteruk M, Styczyńska M, Barcikowska M, Gabryelewicz T.
    J Alzheimers Dis; 2016 Jul 29; 54(1):157-68. PubMed ID: 27472875
    [Abstract] [Full Text] [Related]

  • 16. Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.
    Alexopoulos P, Werle L, Roesler J, Thierjung N, Gleixner LS, Yakushev I, Laskaris N, Wagenpfeil S, Gourzis P, Kurz A, Perneczky R, Alzheimer’s Disease Neuroimaging Initiative (ADNI).
    Alzheimers Res Ther; 2016 Dec 09; 8(1):51. PubMed ID: 27931251
    [Abstract] [Full Text] [Related]

  • 17. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
    Oláh Z, Kálmán J, Tóth ME, Zvara Á, Sántha M, Ivitz E, Janka Z, Pákáski M.
    J Alzheimers Dis; 2015 Dec 09; 44(4):1303-12. PubMed ID: 25428253
    [Abstract] [Full Text] [Related]

  • 18. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC, Hirni DI, Taylor KI, Berres M, Regeniter A, Gass A, Monsch AU, Sollberger M.
    J Alzheimers Dis; 2015 Dec 09; 44(2):625-33. PubMed ID: 25322924
    [Abstract] [Full Text] [Related]

  • 19. CSF Aβ1-42, but not p-Tau181, differentiates aMCI from SCI.
    Rizzi L, Maria Portal M, Batista CEA, Missiaggia L, Roriz-Cruz M.
    Brain Res; 2018 Jan 01; 1678():27-31. PubMed ID: 29017912
    [Abstract] [Full Text] [Related]

  • 20. Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease.
    Mouton-Liger F, Paquet C, Dumurgier J, Lapalus P, Gray F, Laplanche JL, Hugon J, Groupe d'Investigation du Liquide Céphalorachidien Study Network.
    Biol Psychiatry; 2012 May 01; 71(9):829-35. PubMed ID: 22281122
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.